MEDIVIR, INTERIM REPORT, 1 January - 30 June 2006

• Phase III study on Lipsovir® (ME-609) against labial herpes has started • New license agreement on HIV protease with Tibotec • MIV-21 0 (HIV and hepatitis B) outlicensed to Tibotec for onward clinical development • Extended collaboration agreement on hepatitis C protease with Tibotec • Positive results from preclinical studies on the protease project against COPD • Consolidated net sales were SEK 18.5 (27.2) m in the period 1 January - 30 June 2006. • The loss after tax was SEK -108.4 (-73.4) m; earnings per share were SEK -8.40 (-5.69) FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 8 5468 3123 or +46 (0)70 853 7292. FORTHCOMING FINANCIAL INFORMATION The Nine-month Interim Report will be published on 23 October 2006. The Financial Statement for 2006 will be published on 14 February 2007. The Three-month Interim Report will be published on 24 April 2007. Medivir’s financial reports are available on its Website, www.medivir.com from these dates under the ‘Investor/Media’ heading.